Clinical trials

23

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Prospective Study of Ultrahypofractionated Proton Beam Therapy for Localized Prostate Cancer

The goal of this prospective observational cohort study is to evaluate the long-term efficacy and safety of ultrahypofractionated proton beam therapy in patients with localized prostate cancer and to identify clinical and treatment-related factors associated with oncologic outcomes and treatment-related toxicity. The main questions it aims to answer are: What are the long-term biochemical recurrence-free survival, clinical progression-free survival, overall survival, and acute and late treatment-related toxicity outcomes following ultrahypofractionated proton beam therapy? Which clinical characteristics, treatment planning parameters, and patient-reported outcomes are predictive of long-term oncologic outcomes and treatment-related toxicity? Participants will: Receive protocol-based ultrahypofractionated proton beam therapy (35-40 Gy\[RBE\] in 5 fractions). Undergo routine clinical evaluation, laboratory testing including prostate-specific antigen (PSA), and imaging studies according to the institutional follow-up schedule. Complete patient-reported outcome questionnaires (EPIC-CP and Visual Analog Scale \[VAS\]) before treatment and during follow-up. Be followed prospectively to assess biochemical recurrence, clinical progression, survival outcomes, and acute and late treatment-related toxicities.

Participants needed: 50
Trial details
Age: 19+Biological sex: MaleType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Jul 13, 2026Locations: 1
Eligibility criteria

Histologically confirmed localized adenocarcinoma of the prostate. [+5]

Residual or recurrent prostate cancer following prior radical prostatectomy. [+5]

Status: Recruiting

The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy

The aim of this study is to evaluate the effectiveness and safety of mitomycin-c and gemcitabine sequential instillation in BCG unresponsive high risk non-muscle invasive bladder cancer patients.

Participants needed: 82
Trial details
Phase: Phase 2Age: 20+Biological sex: AllType: InterventionalSponsor: National Cancer Center, KoreaUpdated: May 29, 2026Locations: 1
Eligibility criteria

a patient over the age of 20 [+5]

Patient diagnosed with muscle-invasive bladder cancer at TURBT [+19]

Status: Recruiting

Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)

Primary stage III-IV epithelial ovarian cancer randomizing between interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC)

Participants needed: 520
Trial details
Phase: Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Feb 13, 2026Locations: 10
Eligibility criteria

Signed and written informed consent, [+7]

Diagnosed with non-epithelial ovarian carcinoma or borderline ovarian tumor [+12]

Status: Not yet recruiting

Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often persistent adverse effect of oxaliplatin- and paclitaxel-based chemotherapy. While exercise is frequently recommended for patients with CIPN, it remains unclear whether exercise mitigates neuropathic injury itself or primarily improves physical function and quality of life. This randomized controlled trial evaluates the effects of exercise on CIPN during and after chemotherapy. Patients receiving oxaliplatin for colorectal cancer or paclitaxel for gynecologic cancer are randomized to an exercise intervention or usual-care control. Neuropathy severity is assessed using objective neurophysiological measures, blood biomarkers, and validated clinical and patient-reported outcomes.

Participants needed: 140
Trial details
Age: 19-75Biological sex: AllType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Feb 10, 2026Locations: 1
Eligibility criteria

Diagnosis of colorectal cancer (oxaliplatin cohort) or gynecologic cancer (pacli... [+3]

Pre-existing peripheral neuropathy from other causes [+3]

Status: Not yet recruiting

First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment

This study aims to evaluate the efficacy and safety of lenvatinib as first-line therapy in patients with Child-Pugh class B HCC who are unsuitable for curative treatment.

Participants needed: 50
Trial details
Phase: Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Jan 7, 2026
Eligibility criteria

Signed informed consent [+16]

Fibrolamellar carcinoma or sarcomatoid carcinoma [+8]

Status: Recruiting

A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatocellular Carcinoma (HCC) With Vascular Invasion

In the present study, we aim to investigate the efficacy and safety of concurrent therapy of Immunotherapy based combination therapy and Radiotherapy in patients with advanced HCC showing macrovascular invasion.

Participants needed: 128
Trial details
Phase: Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Dec 26, 2025Locations: 2
Eligibility criteria

Signed informed consent form [+19]

Fibrolamellar carcinoma or sarcomatoid carcinoma [+17]

Status: Recruiting

Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer

To compare outcomes between the CRS group and the control group in patients with recurrent epithelial ovarian cancer who have undergone chemotherapy

Participants needed: 80
Trial details
Phase: Phase 2Age: 19-80Biological sex: FemaleType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Sep 12, 2025Locations: 1
Eligibility criteria

Patients with histologically confirmed epithelial ovarian cancer, fallopian tube... [+19]

Patients with non-epithelial ovarian cancer or borderline ovarian tumors. [+18]

Status: Not yet recruiting

Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer

To evaluate the efficacy and safety of intravesical hyaluronic acid (HA) instillation therapy for the prevention of radiation-induced cystitis in patients undergoing radiotherapy for bladder cancer.

Participants needed: 54
Trial details
Age: 19+Biological sex: AllType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Aug 15, 2025Locations: 1
Eligibility criteria

Pathologic confirmed Muscle-Invasive Urothelial Carcinoma I. Clinical stage: T2-... [+5]

Present of distant metastasis (M1) [+7]

Status: Not yet recruiting

A Study to Evaluate the Effectiveness of a Web-based Tool for Fertility Preservation in Cancer Patients

\[Background\] The number of young cancer patients is increasing, and they may experience impairment or loss of reproductive function due to cancer treatments such as surgery, radiation therapy, and chemotherapy. Although various medical methods to preserve fertility have been developed, due to the complexity and medical specialization of these methods, there is an urgent need to support understanding and decision-making regarding these options in clinical practice. While referrals to fertility specialists for counseling are possible, most young cancer patients do not receive such consultations before treatment. Even those who do often report decisional conflict due to confusion about the information and difficulty in reflecting personal values in the decision-making process. Although decision aids have been developed in other countries, cultural, linguistic, and healthcare system differences make it difficult to apply these tools in Korea. Therefore, there is a need to develop a decision aid tailored to female cancer patients in Korea for use in local clinical settings to support fertility preservation decisions. \[Study Objective\] To develop a web-based decision aid and evaluate its impact on decisional conflict, fertility preservation-related knowledge, decision self-efficacy, depression, and quality of life, in order to assess the effectiveness of the decision aid. \[Study Hypothesis\] The use of a web-based decision aid for fertility preservation will: Reduce decisional conflict experienced by cancer patients during the decision-making process; Improve fertility preservation-related knowledge and decision self-efficacy; Reduce levels of depression and improve quality of life. \[Study Plan\] 1. Study Design * Randomized clinical study * Prospective study * Two-arm randomized controlled trial (RCT) 2\. Study Method Female cancer patients visiting the outpatient clinic of the National Cancer Center will be screened to determine eligibility based on inclusion and exclusion criteria. Patients who meet the criteria and voluntarily agree to participate will be enrolled in the study. Participants will be randomly assigned to either the intervention group (who will use the decision aid) or the control group (who will receive standard cancer treatment as planned at the Cancer Center without any special tools). The decision aid will be provided to the intervention group immediately after randomization. The control group will not receive any additional tools. Outcomes will be measured at three time points for the intervention group: before the intervention (T0), one week after the intervention (T1), and one month after the intervention (T2). For the control group, measurements will be taken at the same time points: immediately after randomization (T0), one week later (T1), and one month later (T2).

Participants needed: 32
Trial details
Age: 18-40Biological sex: FemaleType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Jun 26, 2025
Eligibility criteria

Female cancer patients aged 18 to 40 who received treatment at the National Canc... [+2]

Patients who had already lost fertility prior to participating in the study [+1]

Status: Not yet recruiting

Knowledge-enhanced Digital Intervention to Prevent Low Anterior Resection Syndrome

Low anterior resection syndrome refers to changes in bowel habits such as frequent defecation, urgent defecation, and fecal incontinence, which result in decreased bowel function. It occurs very commonly after surgery for colorectal cancer, especially rectal cancer, and symptoms appear severely immediately after surgery, followed by a recovery process. It is known that symptoms improve significantly after one year of surgery, but in some patients, symptoms persist, which significantly affects the quality of life and causes social problems. There is no established treatment method for low anterior resection syndrome, and accurate evaluation and customized treatment are required according to the patient's surgical or radiotherapy treatment content and symptoms. It is also important to monitor the change in symptoms during the treatment process, and a customized step-by-step treatment strategy for such patients is required. However, such a customized step-by-step treatment strategy for such patients is very complex, and there are no clear guidelines to date, and the research design for some clinical trials has been recently reported. The purpose of this study was to develop an app-based Patient-Reported Outcome (PRO) standardized questionnaire for patients after rectal cancer surgery to systematically collect and monitor symptom information, establish a multidisciplinary management plan tailored to patients, and provide education and treatment to improve the quality of life of rectal cancer survivors. A management program utilizing a research device (app) can reduce the incidence of Major LARS after rectal cancer surgery compared to standard treatment.

Participants needed: 320
Trial details
Age: 20-70Biological sex: AllType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Jun 27, 2025
Eligibility criteria

Adults aged 20-70 years [+4]

If you are receiving chemotherapy or radiotherapy at the time of consent [+4]

Status: Recruiting

Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma

\[Study objectives\] To evaluate the efficacy and safety of the combined treatment of radiotherapy and endoscopic intraductal radiofrequency ablation in patients with locoregional extrahepatic cholangiocarcinoma.

Participants needed: 53
Trial details
Age: 20+Biological sex: AllType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Jun 19, 2025Locations: 1
Eligibility criteria

Patients 20 years of age or older, who voluntarily agree to participate in the s... [+1]

Patients who refuse to sign the informed consent [+5]

Status: Recruiting

Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

* Clinical trial phase: Phase 2 * Intervention model: Control group * Group allocation: Randomized controlled trial * Research perspective: Prospective study * Participating centers: Multicenter study * Definition of the intervention period: Based on the RECIST 1.1 guidelines, patients will receive treatment until dropout due to disease progression or unacceptable toxicity related to the trial drug. Patients will be followed up with to assess survival every 2 months until either death or the end of the trial, whichever is first. * The intervention period is from the date of IRB approval to December 31st, 2025 * The follow-up duration is one year, and the statistical analysis duration is six months * The total research period is from the date of IRB approval to June 30th, 2026

Participants needed: 98
Trial details
Phase: Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Jun 18, 2025Locations: 1
Eligibility criteria

Patients aged at least 19 years old, diagnosed with unresectable pancreaticobili...

Patients who refuse to sign the consent form Patients who have previously experi...

Status: Recruiting

Development and Application of Intervention Program to Improve Mental Health and Quality of Life of Solid Tumor Survivors and Caregivers

The research team will assess the psychological abilities like cognitive(how you think and figure things out) and psycho-social(the well-being at the intersection of the internal workings and external experience) functions of young patients who are diagnosed with solid tumor and their primary caregivers. After assessing the psychological abilities, the research team will provide counseling and educational sessions developed by the team. The sessions are provided on a 1:1 basis to each of the participants to verify whether the sessions helped to improve the quality of life, including mental health.

Participants needed: 120
Trial details
Age: 10-24Biological sex: AllType: InterventionalSponsor: National Cancer Center, KoreaUpdated: May 14, 2025Locations: 3
Eligibility criteria

Those between the ages of 10 and 24, and diagnosed with pediatric solid tumor, w... [+2]

Those who disagree to participate as a research subject. [+4]

Status: Not yet recruiting

Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients.

This study is a multicenter randomized controlled trial conducted in Korea. A parallel, two-group randomized design will be with thyroid stimulating hormone suppression therapy group(low TSH group; intervention) is different from the wIthout thyroid stimulating hormone (TSH) suppression therapy group(high TSH group; control).

Participants needed: 578
Trial details
Age: 19-79Biological sex: AllType: InterventionalSponsor: National Cancer Center, KoreaUpdated: May 14, 2025
Eligibility criteria

Thyroid nodule of 1.0 cm or less confirmed as Bethesda category V (suspicious fo... [+2]

Hyperthyroidism [+2]

Status: Not yet recruiting

Shared Decision-Making for Determining Treatment Strategies in Low-Risk Thyroid Cancer

This study is a multicenter cluster-randomized controlled trial conducted in Korea. A parallel, two-group cluster-randomized design will be used to test whether the Shared decision-making Group (SDM; intervention) is different from the Standard Care Group (SC; control).

Participants needed: 310
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Apr 30, 2025
Eligibility criteria

Adults aged 18 years or older with a thyroid nodule of 1.0 cm or less confirmed... [+1]

Patients who cannot undergo regular follow-up or are expected to have difficulti... [+1]

Status: Recruiting

Surgical Outcome of BCS Using ICG-F in Breast Cancer Patients After Preoperative Chemotherapy

Neoadjuvant chemotherapy for advanced breast cancer has led to an increased rate of breast-conserving surgery (BCS) in these patients. As the demand for preoperative localization methods grows among surgeons performing BCS, traditional localization techniques have shown limitations. For non-palpable breast lesions, preoperative localization has commonly been achieved using ultrasound-guided skin markings or needle localization. However, these methods present challenges, including difficulty in depth localization for patients with large breasts and limitations in real-time re-verification during surgery due to air artifacts after incision. Needle localization, although commonly used, is invasive and poses risks such as displacement or detachment of the needle. Indocyanine green (ICG), a fluorescent dye that appears green to the naked eye and is detectable by near-infrared (NIR) cameras, has been widely and safely used in clinical practice via intravenous or subcutaneous administration. Recently, ICG combined with NIR imaging has been adopted for sentinel lymph node biopsy in breast cancer and melanoma surgeries and is increasingly used as a localization method for various tumors, replacing conventional techniques. A preliminary study (IRB No. NCC2016-0071) conducted at the institution evaluated ICG injection and NIR fluorescence imaging for tumor localization in early breast cancer patients undergoing BCS. The study demonstrated the efficacy of ICG-based localization in reducing the rate of positive surgical margins. The objective of this study is to evaluate the effectiveness of ICG-guided tumor localization with NIR fluorescence imaging in patients with advanced breast cancer treated with neoadjuvant chemotherapy. It is hypothesized that this technique will allow for more accurate tumor excision compared to conventional methods, ultimately improving surgical outcomes.

Participants needed: 128
Trial details
Age: 18+Biological sex: FemaleType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Mar 13, 2025Locations: 1
Eligibility criteria

The Patient with locally advanced breast cancer who is eligible for breast-conse... [+3]

The patient who requires total mastectomy after receiving neoadjuvant chemothera... [+5]

Status: Recruiting

Photo-medicine-Guided Dual Approach for Reoperation of Sentinel Lymph Nodes in Locally Recurrent Breast Cancer Patients

Sentinel lymph node biopsy (SLNB) is essential for staging and treatment planning in early breast cancer patients. As a less invasive procedure, it has replaced axillary lymph node dissection (ALND) by reducing complications and improving patient outcomes. However, the 10-year local recurrence rate for breast cancer is approximately 2-10%, and the role of SLNB in the surgical management of recurrent breast cancer remains unclear. According to the NCCN guidelines and Korean Breast Cancer Treatment Recommendations, surgical management for recurrent breast cancer includes mastectomy and axillary lymph node surgery for patients who have previously undergone breast-conserving surgery and radiotherapy. For axillary recurrence, surgery is recommended if feasible, followed by radiotherapy. Conversely, the ASCO guidelines recommend SLNB for surgically resectable recurrent breast cancer, and recent studies have reported promising outcomes for repeat sentinel lymph node biopsy (reSLNB). Vugts G et al. demonstrated an 80.1% tumor-negative rate with reSLNB, suggesting that ALND could be avoided in many cases. Although reSLNB offers the advantage of reducing unnecessary invasive procedures and associated complications, challenges remain due to disrupted lymphatic pathways in patients who have previously undergone surgery and radiotherapy. Additionally, research on the long-term prognosis of these patients is still limited. This study aims to evaluate the detection rate of sentinel lymph nodes using a photo-medicine-based dual localization technique that combines traditional radiotracer methods with indocyanine green-fluorescence (ICG-F) in patients undergoing reSLNB for locally recurrent breast cancer.

Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Jan 17, 2025Locations: 1
Eligibility criteria

Patients with ipsilateral locally recurrent breast cancer who previously underwe... [+3]

Patients with distant metastases. [+3]

Status: Recruiting

Comparison of Endoscopic Resection and Surgery for Early Gastric Cancer With Undifferentiated Histological Type

This multi-center, randomized controlled trial is designed to evaluate clinical effectiveness and cost-effectiveness of ESD for undifferentiated type of EGC meeting the expanded indication compared with surgery.

Participants needed: 708
Trial details
Age: 19-75Biological sex: AllType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Dec 27, 2024Locations: 1
Eligibility criteria

Patients who are diagnosed with undifferentiated type EGC (signet ring cell carc... [+2]

Patient age: < 19 years or age > 75 years [+6]

Status: Recruiting

Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients

This study aimed to investigate the effect of low-dose (100 mg) asprin on the prevention of gastric cancer in the early gastric cancer patients with negative H. pylori status who underwent endoscopic submucosal dissection.

Participants needed: 1,700
Trial details
Phase: Phase 3Age: 19-70Biological sex: AllType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Dec 27, 2024Locations: 10
Eligibility criteria

Men and women aged 19-70 years who underwent endoscopic resection for high-grade... [+3]

Patients who received aspirin for the secondary prevention of cardiovascular dis... [+14]

Status: Recruiting

A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

Using gefitinib or Osimertinib, an EGFR tyrosine kinase inhibitor (TKI), in patients with active mutations in epithelial cell growth factor receptors (EGFR), 70% response rate (CR+PR) and 90% disease control rate (CR+PR+SD) compared to the current non-small cell therapy, which is significant in the EFRT treatment. However, resistance causes recurrence in most patients. Therefore, it is necessary to develop a more effective treatment. Recently, in Japan, combined allotinib and bevacizumab therapy as primary therapy in non-small cell lung cancer patients with EGFR mutation improved PFS statistically significantly compared to allotinib monotherapy, suggesting the possibility of a new treatment (Hazard ratio 0.605, 95% CI 0.417-0.877, P=0.016). In addition, subsequent osmutinib and bevacizumab combination therapy showed a significant difference in PFS in the smoker group, although they did not show significant improvement in PFS in the entire patient group. (Hazard ratio 0.605, 95% CI 0.417-0.877, P=0.016). Since EGFR mutated lung cancer is highly frequent in Korea, it is necessary to develop more effective treatments for such patients. Therefore, we propose this clinical trial to find out the efficacy of lasertinib and bevacizumab combination therapy.

Participants needed: 120
Trial details
Phase: Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Dec 5, 2023Locations: 5
Eligibility criteria

Histologically confirmed patients with locally progressive or metastatic non-sma... [+22]

Average of corrected QT intervals at rest (QTc intervals corrected by Fredericia... [+2]

Status: Recruiting

Development of Asian Consortium for Data Collection and Clinical Trial of CNS Tumors

\<Purpose of the Research\> * Primary Establishing an Asian consortium to establish a database of pediatric CNS tumors in the prospective manner The target disease of this research focuses on pediatric tumors, and initially the registration of patients with CNS GCT will begin first. * Secondary Developing clinical protocols for pediatric CNS tumors based in Asia \<Duration of Research Participation\> Registration period for research subjects: 2022-08-01 - 2027-12-31 Duration of medical records to be utilized: to 2030-12-31 Total projected duration of research: IRB approved to 2032-12-31 Interim assessment of data quality and integrity: 6 Mo after Data collection Evaluation for the Adaptation of Protocols: 1 and 2 years after the initiation of the study Analysis of Quality of Life and other questionnaires: 3 and 5 years Interim Analysis of all data: 5 years (2027) Final analysis of treatment outcome: 2032

Participants needed: 400
Trial details
Biological sex: AllType: ObservationalSponsor: National Cancer Center, KoreaUpdated: Aug 8, 2023Locations: 1Duration: 1 Year
Eligibility criteria

A patient who was diagnosed with CNS GCT and agreed to participate in the resear... [+3]

Status: Not yet recruiting

Feasibility Study of Sentinel Navigation Surgery in Early Gastric Cancer Using Fluorescence (SENORITA4)

SENORITA 1 trial showed laparoscopic sentinel lymph node biopsy and stomach preserving surgery in early gastric cancer can increase the quality of life. (Ryu KW et al. JCO 2022) The radioactive isotope is difficult to use because of the hazard of radiation and shortage of materials. The aim of this study is to investigate whether laparoscopic sentinel lymph node biopsy and stomach-preserving surgery using only fluorescence is feasible.

Participants needed: 203
Trial details
Age: 20-80Biological sex: AllType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Aug 7, 2023Locations: 7
Eligibility criteria

single lesion of adenocarcinoma in preoperative endoscopic biopsy clinical stage... [+6]

indication of endoscopic submucosal resection [+4]

Status: Recruiting

Survival Rates and Quality of Life According to Follow-up Period After Gastrectomy for Gastric Cancer (STOFOLUP)

This study is a multi-center, prospective, randomized controlled study. The aim of this study is to compare survival rates and to observe quality of life and nutritional status according to follow-up period in patients who underwent radical gastrectomy for stage 2 or 3 gastric cancer.

Participants needed: 886
Trial details
Age: 19+Biological sex: AllType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Oct 27, 2021Locations: 16
Eligibility criteria

Patients aged 19 years or more [+2]

Vulnerable patients such as pregnant and intellectual disability [+4]